Bupropion, a possible antidepressant without negative effects on alcohol relapse

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• The impact of antidepressants on alcohol consumption, particularly during relapse, remains unclear.
• Previous research indicated increased alcohol intake with Selective Serotonin Reuptake Inhibitors (SSRIs) in animal models.
• The effects of atypical antidepressants like Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors (SNDRIs) on alcohol relapse are not well-established.

Purpose of the Study:

• To compare the effects of fluoxetine (SSRI) and bupropion (SNDRI) on alcohol consumption during relapse in a rat model.
• To investigate the influence of these antidepressants on glutamatergic and endocannabinoid signaling systems in the prefrontal cortex.

Main Methods:

• Rats trained for alcohol self-administration were treated with vehicle, fluoxetine, or bupropion during abstinence.
• Alcohol consumption was monitored during a 3-week relapse period.
• Gene and protein expression of glutamatergic and endocannabinoid systems in the prefrontal cortex were analyzed.

Main Results:

• Fluoxetine treatment led to a sustained increase in alcohol consumption during relapse.
• Bupropion treatment did not alter alcohol consumption levels.
• Both antidepressants induced distinct changes in the glutamate and endocannabinoid systems.

Conclusions:

• SSRIs may exacerbate alcohol consumption during relapse, whereas SNDRIs show no such effect.
• Antidepressant-induced alterations in glutamatergic and endocannabinoid systems are linked to changes in alcohol intake.
• Findings suggest potential for novel therapeutic approaches for comorbid depression and alcohol use disorders.